Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-12-12
2006-12-12
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S330000, C435S332000, C435S344000, C530S387300, C530S387700, C530S388800, C530S391300, C530S391700, C530S387100, C530S350000, C536S023500, C424S138100, C424S181100
Reexamination Certificate
active
07148038
ABSTRACT:
Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5514787 (1996-05-01), Atkinson
patent: 5552381 (1996-09-01), Atkinson
patent: 5665570 (1997-09-01), Yamagata et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5703046 (1997-12-01), Atkinson
patent: 5760185 (1998-06-01), Kimachi et al.
patent: 5773247 (1998-06-01), Maeda et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5846715 (1998-12-01), Purcell et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5932225 (1999-08-01), Wallach et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6086876 (2000-07-01), Karp et al.
patent: 6110724 (2000-08-01), Nakagomi et al.
patent: 6117653 (2000-09-01), Thoma
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6210671 (2001-04-01), Co
patent: 6218520 (2001-04-01), Atkinson
patent: 6221644 (2001-04-01), Berka et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6350861 (2002-02-01), Co et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 2002/0115065 (2002-08-01), Logtenberg et al.
patent: 0 519 596 (1992-12-01), None
patent: WO 01/27160 (2001-04-01), None
patent: WO 01/88537 (2001-11-01), None
patent: WO 02/18948 (2002-03-01), None
patent: WO-03/032814 (2003-04-01), None
patent: WO-03/032814 (2003-04-01), None
Varsano et al ., Clin Exp Immunol, 113: pp. 173-183, 1998.
Bjorge et al., Int. J. Cancer, 70: pp. 14-25,1997.
Juhl et al ., J. Surg. Oncol,64: pp. 222-230, 1997.
Allen, B.J. et al. (2001). “In Vitro and Preclinical Targeted Alpha Therapy for Melanoma, Breast, Prostate and Colorectal Cancers,”Crit. Rev. Oncol. Hmatol.39:139-146.
Donin, N. et al. (2003). “Complement Resistance of Human Carcinoma Cells Depends on Membrane Regulatory Proteins, Protein Kinases and Sialic Acid,”Clin. Exp. Immunol.131:254-263.
Fracasso, G. et al. (2002). “Anti-tumor Effects of Toxins Targeted to the Prostate Specific Membrane Antigen,”Prostate53:9-23.
Noe, K.H. et al. (1999). “Requirements for Measles Virus Induction of Rantes Chemokine in Human Astrocytoma-Derived U373 Cells,”J. Virol.73(4):3117-3124.
Seya, T. et al. (1993). “Membrane Co-Factor Protein (MCP, CD 46) in Seminal Plasma and on Spermatozoa in Normal and ‘Sterile’ Subjects,”Eur. J. Immunol.23:1322-1327.
Andrew, S.M. et al. (1990). “Tumor Localization by Combinations of Monoclonal Antibodies in a New Human Colon Carcinoma Cell Line (LIM1899),”Cancer Res.50: 5225-5230.
Aruffo, A. and Seed, B. (1987). “Molecular Cloning of a CD28 cDNA by High-Efficiency COS Cell Expression System”Proc. Natl. Acad. Sci. USA84:8573-8577.
Azuma, A. et al. (1995). “Augmented Lung Adenocarcinoma Cytotoxicity by the Combination of a Genetically Modified Anti-Lewis Y Antibody and Antibodies to Complement Regulatory Proteins,”Scand. J. Immunol.42: 202-208.
Ballard, L. et al. (1987). “A Polymorphism of the Complement Regulatory Protein MCP (Membrane Cofactor Protein or gp45-70),”J Immunol138(11):3850-3855.
Bjørge, L. et al. (1996). “Characterisation of the Complement-Regulatory Proteins Decay-Acceleraing Factor (DAF, CD55) and Membrane Cofactor Protein (MCP, CD46) on a Human Colonic Adenocarcinoma Cell Line,”Cancer Immunol. Immunother.42:185-192.
Bjørge, L. et al. (1997). “Complement-Regulatory Proteins in Ovarian Malignancies,”Int. J. Cancer70:14-25.
Blok, V.T. et al. (2000). “A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage,”Lab. Invest.80(3):335-44.
Blom, D-J. et al. (1997). “Lack of Effect of Different Cytokines on Expression of Membrane-Bound Regulators of Complement Activity on Human Uveal Melanoma Cells,”J Interferon Cytokine Res17(11):695-700.
Brown, b. A. et al. (1987). “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Research47:3577-3583.
Cho, S-W. et al. (1991). “Characterization of Three Monoclonal Antibodies to Membrane Co-Factor Protein (MCP) of the Complement System and Quantification of MCP by Radioassay,”Clin. Exp. Immunol.83:257-261.
Cole, J.L. et al. (1985). “Identification of an Additional Class of C3-Binding Membrane Proteins of Human Peripheral Blood Leukocytes and Cell Lines,”Proc. Natl. Acad. Sci. USA82:859-869.
Daugherty, B.L. et al. (1991). “Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Munine Monoclonal Antibody Directed Against the CD 18 Component of Leukocyte Integrins,”Nucleic Acids Research19(9):2471-2476.
Dillman, R. O. et al. (1988). “Superiority of an Acid-Labile Daunorubicin—Monoclonal Antibody Immonoconjugate compared to Free Drug,”Cancer Research48:6097-6102.
Gennaro, A. R. (2000). Remington:The Science and Practice of Pharmacy.20thedition, Mack Publishing, Table of Contents only.
Goldenberg, D. M., ed. (1995).Cancer Therapy with Radiolabeled Antibodies.CRC Press. (Table of Contents).
Gorter, A. et al. (1996). “Expression of CD46, CD55, and CD 59 on Renal Tumor Cell Lines and Their Role in Preventing Complement-Mediated Tumor Cell Lysis,”Lab. Invest.74(6):1039-1049.
Hofman, P. et al. (1994). “High Expression of the Antigen Recognized by the Monoclonal Antibody GB24 on Human Breast Carcinomas: A Preventive Mechanism of Malignant Tumor Cells Against Complement Attack?”Breast Cancer Res. Treat.32:213-219.
Hsi, B.L. (1988). “Monoclonal Antibody GB24 Recognizes a Trophoblast-Lymphocyte Cross-Reactive Antigen,”Am J Reprod Immunol Microbiol18(1):21-27.
Jarvis, G.A. et al. (1997). “Expression and Function of Complement Regulatory Proteins CD46, CD55, and CD59 in Prostate Cancer,”J. Allergy Clin. Immunol99(No. 1, Part 2): S215, Abstract No. 870.
Jones, P. T. et al. (1986). “Replacing the Complimentarity-Determining Regions in a Human Anitbody with Those from a Mouse,”Nature321:522-525.
Juhl, H. et al. (1997) “Frequent Expression of Complement Resistance Factors CD46, CD55, and CD59 on Gastrointestinal Cancer Cells Limits the Therapeutic Potential of Monoclonal Antibody 17-1A,”J. Surg. Oncol.64:222-230.
Kinuagasa, N. et al. (1999). “Expression of Membrane Cofactor Protein (MCP, CD46) in Human Liver Diseases,”Br J Cancer.80(11):1820-1825.
Kohler, G. and Milstein, C. (1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-497.
Koretz, K. et al. (1993). “Expression of CD59, A Complement Regulator Protein and a Second Ligand of the CD2 Molecule, and CD46 in Normal and Neoplastic Colorectal Epithelium,”Br. J. Cancer68:926-931.
Liu, A.Y. (2000). “Differential Expression of Cell Surface Molecules in Prostate Cancer Cells,”Cancer Res.60(13):3429-3434.
LoBuglio, A. F. (1989). “Mouse/Human Chimeric Monoclonal antibody in Man: Kinetics and Immune response,”Proc. Natl. Acad. Sci. USA86:4220-4224.
Lublin, D.M. et al. (1988). “Molecular Cloning and Chromosomal Localization of Human Membrane Cofactor Protein (MCP); Evidence for Inclusion in the Multigene Family of Complement-Regulatory Proteins,”J. Exp. Med.168(1):181-194.
Mäenpää, A. et al. (1996). “Expression of Complement Membrane Regulators Membrane Cofactor Protein (CD46), Decay Accelerating Factor (CD55), and Protectin (CD59) in Human Malignant Gliomas,”Am. J. Pathol.148(4):1139-1152.
Magyarlaki, T. et al. (1996). “Immunohistoch
Morrison & Foerster / LLP
Raven biotechnologies, inc.
Rawlings Stephen L.
LandOfFree
Antibodies that bind to cancer-associated antigen CD46 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that bind to cancer-associated antigen CD46 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind to cancer-associated antigen CD46 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3684588